We are live on ! Find out more
EU

Emory University Portfolio holdings

AUM $267M
1-Year Est. Return 48.26%
This Fund
S&P 500
This Quarter Est. Return
+5.99%
1 Year Est. Return
+48.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$142M
AUM Growth
-$208K
Cap. Flow
+$2.42M
Cap. Flow %
1.71%
Top 10 Hldgs %
51.56%
Holding
51
New
6
Increased
20
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$2.43M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$2.39M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.29M
4
BPMC
Blueprint Medicines
BPMC
+$2.27M
5
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$2.27M

Top Sells

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$2.75M
2
ARGX icon
argenx
ARGX
+$2.35M
3
ATNX
Athenex, Inc. Common Stock
ATNX
+$2.31M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$2.21M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$2.14M

Sector Composition

Rank Sector Weight
1 Healthcare 50.39%
2 Financials 32.94%
3 Consumer Discretionary 8.74%
4 Industrials 2.71%
5 Real Estate 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRK.A icon
1
Berkshire Hathaway Class A
BRK.A
$1.06T
$37.2M 26.22%
117
– –
JD icon
2
JD.com
JD
$40B
$12M 8.48%
397,528
– –
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
$4.01M 2.82%
+86,567
New +$2.43M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.23B
$3.21M 2.26%
131,041
-99,851
-43% -$1.5M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.16M 2.22%
+30,680
New +$2.39M
RARX
6
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.94M 2.07%
97,916
-21,043
-18% -$482K
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
$2.86M 2.01%
59,905
+9,147
+18% +$368K
EIDX
8
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$2.61M 1.83%
+83,836
New +$2.27M
BPMC
9
DELISTED
Blueprint Medicines
BPMC
$2.6M 1.83%
+27,551
New +$2.27M
MGTX icon
10
MeiraGTx Holdings
MGTX
$1.15B
$2.57M 1.81%
+95,462
New +$1.97M
AMRN
11
Amarin Corp
AMRN
$292M
$2.56M 1.8%
6,613
-140
-2% -$51.3K
GHDX
12
DELISTED
Genomic Health, Inc.
GHDX
$2.5M 1.76%
42,966
+14,347
+50% +$850K
TVTX icon
13
Travere Therapeutics
TVTX
$5.27B
$2.48M 1.75%
123,600
+12,973
+12% +$256K
WVE icon
14
Wave Life Sciences
WVE
$1.12B
$2.46M 1.74%
94,475
+31,041
+49% +$870K
NBIX icon
15
Neurocrine Biosciences
NBIX
$17.2B
$2.45M 1.72%
29,020
+733
+3% +$60.2K
BCRX icon
16
BioCryst Pharmaceuticals
BCRX
$2.36B
$2.45M 1.72%
645,583
+380,570
+144% +$2.29M
INCY icon
17
Incyte
INCY
$23.4B
$2.44M 1.72%
28,714
+196
+0.7% +$15.7K
MDGL icon
18
Madrigal Pharmaceuticals
MDGL
$12.8B
$2.42M 1.71%
23,131
+5,499
+31% +$589K
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$4.38B
$2.41M 1.7%
90,188
-12,398
-12% -$317K
FOLD
20
DELISTED
Amicus Therapeutics
FOLD
$2.4M 1.69%
192,533
-16,321
-8% -$207K
HRTX icon
21
Heron Therapeutics
HRTX
$89.1M
$2.4M 1.69%
129,020
+42,543
+49% +$850K
ALXN
22
DELISTED
Alexion Pharmaceuticals
ALXN
$2.39M 1.68%
18,235
-194
-1% -$25K
SGEN
23
DELISTED
Seagen Inc. Common Stock
SGEN
$2.33M 1.64%
33,593
+225
+0.7% +$15.8K
BMRN icon
24
BioMarin Pharmaceuticals
BMRN
$11.5B
$2.25M 1.58%
26,278
+902
+4% +$77.2K
ONC
25
BeOne Medicines Ltd
ONC
$32.4B
$2.21M 1.55%
17,807
-232
-1% -$29.4K
1
2 3

Similar funds

CFG
Cambridge Financial Group Columbus, Ohio $267M AUM 31.62% 1-Year Est. Return
PC
Packer & Co Cottesloe, Australia $267M AUM
ALC
Alexander Labrunerie & Co Columbia, Missouri $267M AUM 21.24% 1-Year Est. Return
TWM
TCFG Wealth Management Laguna Niguel, California $267M AUM 39.78% 1-Year Est. Return
IP
Indigo Partners Phoenix, Arizona $267M AUM 9% 1-Year Est. Return
SP
ShawSpring Partners Boston, Massachusetts $268M AUM 28.19% 1-Year Est. Return
EAIC
Empower Annuity Insurance Company Hartford, Connecticut $268M AUM 0.28% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

Emory University's Q2 2019 Portfolio in Review

As of Q2 2019, Emory University held 51 positions worth $142M, down 0.15% from $142M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Emory University's Q2 2019 filing shows 6 new, 20 increased, 15 reduced and 5 closed positions. Its largest new stake was Array Biopharma Inc: 86,567 shares worth $4.01M. The largest sale was Solid Biosciences, an estimated $2.75M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 53% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Emory University's largest Q2 2019 buy was Array Biopharma Inc: 86,567 shares worth $4.01M.
  • Emory University added most to BioCryst Pharmaceuticals in Q2 2019, an estimated $2.29M increase.
  • Emory University's biggest Q2 2019 reduction was Ascendis Pharma A/S, cutting an estimated $1.69M.
  • Emory University fully exited Solid Biosciences in Q2 2019, selling an estimated $2.75M.
  • Emory University's ten largest holdings make up 52% of its $142M portfolio in Q2 2019.
  • Emory University opened 6 new positions and closed 5 in Q2 2019.
  • Emory University's portfolio value fell 0.15% quarter-over-quarter to $142M.

Based on Emory University's 13F filing for Q2 2019, filed 14 Aug 2019.